Egyesült Államok - angol - NLM (National Library of Medicine)

blenheim pharmacal, inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 500 mg - cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis skin and skin structure infections caused by staphylococci and/or streptococci bone infections caused by staphylococci and/or p. mirabilis genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and k. pneumoniae note - culture and susceptibility tests should be initiated prior to and during

Egyesült Államok - angol - NLM (National Library of Medicine)

strategic pharmaceutical solutions, inc. dba vetsource - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis skin and skin structure infections caused by staphylococci and/or streptococci bone infections caused by staphylococci and/or p. mirabilis genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and k. pneumoniae note - culture and susceptibility tests should be initiated prior to and during

Egyesült Államok - angol - NLM (National Library of Medicine)

h.j. harkins company, inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 500 mg - cephalexin capsules, usp are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin capsules, usp are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin capsules, usp in the subsequent prevention of rheumatic fever are not available at present.) - otitis media due to streptococcus pneumoniae, haemophilus influenzae , staphyloccus aureus, streptococcus pyogenes, and moraxella catarrhalis - skin and skin structure infections caused by staphylococcus aureus  and/or streptococcus pyogenes   - bone infections caused by staphylococcus aureus  and/or proteus mirabilis - genitourinary tract infections, includ

Egyesült Államok - angol - NLM (National Library of Medicine)

stat rx usa llc - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 500 mg - cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes bone infections caused by staphylococcus aureus and/or proteus mirabilis genitourinary tract infections, including acute prostatitis, caused by escherichia coli,

Egyesült Államok - angol - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsules usp are indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes . cephalexin capsules usp are indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis . cephalexin capsules usp are indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin capsules usp are indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis . cephalexin capsules usp are indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella pneumoniae . to reduce the dev

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg;   - capsule - 500 mg - active: cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg   excipient: gelatin   magnesium stearate microcrystalline cellulose titanium dioxide   water  

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 262.94 mg (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: colloidal anhydrous silica; magnesium stearate; lactose; titanium dioxide; brilliant blue fcf; purified water; quinoline yellow; allura red ac; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 525.87 mg (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: magnesium stearate; colloidal anhydrous silica; lactose; titanium dioxide; brilliant blue fcf; quinoline yellow; purified water; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 262.94 mg (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: lactose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; quinoline yellow; allura red ac; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 525.87 mg (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: lactose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; brilliant blue fcf; quinoline yellow; purified water; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.